Aim: To evaluate the intraocular stability and safety of secondary iris-claw IOLs in aphakic patients.
Methods: 18 eyes of 16 patients received iris-claw intraocular lenses (IOLs) to correct for aphakia. Primary outcome measurements included visual acuity (6m Snellen charts), central endothelium cell count (cECC) and intraocular position of the IOL assessed with anterior segment optical coherence tomography (OCT).
Results: Sixteen patients (mean age 66 years; range 16-84 years, axial length 24.44mm) were re-examined 22 months postoperatively (range 12 - 38months). Preoperative decimal BCVA was 0.51, IOP 15.3mmHg, and central ECC 1816/mm2. Postoperative BCVA was 0.68, IOP 13.1mmHg, and central ECC 1626/mm2 (difference over time 176/mm2 = 10.5%, p>0.05). The anterior chamber depth was 4 mm for the eyes <24mm, and 4.34mm for ≥24mm.
Conclusion: Secondary anteriorly iris-claw IOLs appear to be a safe choice to correct aphakia with no significant intermediate postoperative central endothelium cell loss especially in eyes ≥24mm, as distances of the IOL to the central and peripheral cornea proofed consistent.